Biogen Idec
NASDAQ : BIIB

Biogen Idec

September 08, 2005 16:01 ET

Biogen Idec Announces Management Change

CAMBRIDGE, Mass. & SAN DIEGO--(CCNMatthews - Sep 8, 2005) -

Biogen Idec (NASDAQ: BIIB) today announced that Michael Gilman Ph.D., Executive Vice President, Research, is leaving the company, effective November 8, 2005. Alphonse Galdes, Ph.D., Vice President, Drug Discovery, and Rainer Fuchs, Ph.D., Vice President, Research Informatics and Operations, will assume Dr. Gilman's responsibilities on an interim basis. Research will continue to report to William H. Rastetter, Ph.D., Executive Chairman.

Dr. Gilman served as Biogen Idec's Executive Vice President, Research since July 2004. Previously, Dr. Gilman was the company's Senior Vice President, Research, and served in that same capacity for Biogen, Inc. from October 2001 until November 2003.

"We thank Mike for his significant contributions during his six years at Biogen Idec. Under his leadership, Biogen Idec has built on its strong scientific legacy. We wish Mike well in all future endeavors," said Dr. Rastetter.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Contact Information

  • Biogen Idec
    Media:
    Jose Juves, 617-914-6524
    Associate Director, Public Affairs
    or
    Investors:
    Elizabeth Woo, 617-679-2812
    Vice President, Investor Relations